Recombinant Human IL-39 Fc Chimera Protein, CF

Recombinant Human IL-39 Fc Chimera (Catalog # 9990-IL) induces IFN-gamma production in mouse splenocytes. The ED50 for this effect is 50-250 ng/mL.

2 μg/lane of Recombinant Human IL-39 was resolved with SDS-PAGE underreducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Bluestaining, showing bands at 70-77 kDa and 140-160 kDa, respectively.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human IL-39 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its ability to induce IFN-gamma production by mouse splenocytes. The ED₅₀ for this effect is 50-250 ng/mL.
• Source: Human embryonic kidney cell, HEK293-derived human IL-39 (IL-23p19/EBI3) protein
  

  Human EBI3 (Arg21-Lys229, Gln95Cys) Accession # Q14213	GGGSGGGSGGGS	Human IL-23p19 (Arg20-Pro189) Accession # Q9NPF7	IEGRMD	Human IgG1 (Pro100-Lys330)

• Accession #: Q14213, Q9NPF7
• N-terminal Sequence: Arg21 (EBI3)
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 69 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 70-77 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage:
  • 12 months from date of receipt, ≤ -20 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, ≤ -20 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
• Reconstitution Instructions: Reconstitute at 200 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human IL-39 Fc Chimera Protein, CF

• IL-23 p19/EBI3
• IL-23p19/EBI3
• IL-39 (IL-23p19/EBI3)

Background

Interleukin 39 (IL-39) is a member of the IL-12 family of heterodimeric cytokines. IL-12 cytokines are composed of an alpha and beta subunit which, for IL-39 are the IL-23 p19 subunit and the EBI3 subunit, respectively (1-3). The IL-23 p19 subunit of IL-39 is synthesized as a 189 amino acid (aa) precursor protein with a 19 aa signal sequence and a 170 aa mature region. The EBI3 subunit of IL-39 is synthesized as a 229 aa precursor protein that contains a 20 aa signal sequence and a 209 aa mature region. Human and mouse IL-39 share 73% and 62% sequence homology in their IL-23 p19 and EBI3 subunits, respectively. Heterodimer (IL-39) is secreted by LPS-stimulated B cells and GL7(+) activated B cells of lupus-like mice (1, 4). IL-39 signals through IL-23 R/gp130 receptors and mediates inflammatory responses through activation of STAT1 and STAT3 in lupus-like mice (1, 2). IL‐39 induces and/or expands neutrophils in lupus‐prone mice, and IL‐39‐induced neutrophils increase the secretion of B cell activation factor (BAFF) (3). Thus, IL-39 is an important pro-inflammatory cytokine and play important roles in the pathophysiology of autoimmune diseases, including Systemic Lupus Erythematosus (SLE) (2, 4).

1. Wang, X. et al. (2016) Eur J Immunol 46:1343.
2. Hasegawa, H. et al. (2016) Front Immunol 7:479.
3. Wang, X. et al. (2016) Clin Exp Immunol 186:144.
4. Wang, X. et al. (2018) Mol Med Rep 17:1660.

Publications for IL-39 (IL-23p19/EBI3) (9990-IL)(2)

Publications using 9990-IL

• Xiao H, Alisic H, Reiman B, Deng Z, Zhu Z, Givens N, Bai Q, Tait A, Wakefield M, Fang Y IL-39 Reduces Proliferation and Promotes Apoptosis of Bladder Cancer by Altering the Activity of Cyclin E and Fas. Anticancer Res, 2021-05-01;41(5):2239-2245. 2021-05-01 [PMID: 33952450] (Bioassay, Human)
• MA Cassatella, E Gardiman, F Arruda-Sil, F Bianchetto, S Gasperini, M Bugatti, W Vermi, F Larousseri, O Devergne, N Tamassia Human neutrophils activated by TLR8 agonists, with or without IFNgamma, synthesize and release EBI3, but not IL-12, IL-27, IL-35, or IL-39 J. Leukoc. Biol., 2020-06-01;0(0):. 2020-06-01 [PMID: 32480433] (Reference Standard, Human)

Bioinformatics

• Uniprot:
  • Q14213, Q9NPF7()